Curis (CRIS) Change in Receivables (2010 - 2025)
Curis' (CRIS) quarterly Change in Receivables came in at $1.1 million in Q4 2025, up 206.74% YoY from $371000.0 in Q4 2024, and up 131.77% on a QoQ basis from $491000.0 in Q3 2025.
Curis (CRIS) Change in Receivables (2010 - 2025) Analysis & Trends
Curis (CRIS) has 16 years of Change in Receivables data on file, last reported at $1.1 million in Q4 2025.
- Quarterly Change in Receivables rose 206.74% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $2.1 million (up 1183.23% YoY) and the FY2025 annual result came in at $1.0 million, up 85.95% from the prior year.
- Change in Receivables advanced to $1.1 million in Q4 2025, from $491000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $1.1 million in Q4 2025 to a low of -$1.2 million in Q1 2022.
- A 5-year average of $66900.0 and a median of $300000.0 in 2021 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2021 — Change in Receivables surged 1033.33% — and 2023, when it slumped 160.67%.
- Tracing CRIS's Change in Receivables over 5 years: stood at $265000.0 in 2021, then plunged by 66.42% to $89000.0 in 2022, then slumped by 160.67% to -$54000.0 in 2023, then soared by 787.04% to $371000.0 in 2024, then jumped by 206.74% to $1.1 million in 2025.
- The last three Change in Receivables figures came in at $1.1 million (Q4 2025), $491000.0 (Q3 2025), and $437000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Curis | 3.27 Mn | -2.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.14 Mn |
| Dec 31, 2025 | 1.14 Mn |
| Sep 30, 2025 | 491,000.00 |
| Sep 30, 2025 | 491,000.00 |
| Jun 30, 2025 | 437,000.00 |
| Jun 30, 2025 | 437,000.00 |
| Mar 31, 2025 | -1.03 Mn |
| Mar 31, 2025 | -1.03 Mn |
| Dec 31, 2024 | 371,000.00 |
| Dec 31, 2024 | 371,000.00 |
| Sep 30, 2024 | 432,000.00 |
| Sep 30, 2024 | 432,000.00 |
| Jun 30, 2024 | 392,000.00 |
| Jun 30, 2024 | 392,000.00 |
| Mar 31, 2024 | -640,000.00 |
| Mar 31, 2024 | -640,000.00 |
| Dec 31, 2023 | -54,000.00 |
| Dec 31, 2023 | -54,000.00 |
| Sep 30, 2023 | 462,000.00 |
| Sep 30, 2023 | 462,000.00 |